{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:24Z","timestamp":1792130724232,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40265-016-0616-x","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T14:29:19Z","timestamp":1468333759000},"page":"1221-1226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Obeticholic Acid: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"A.","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"616_CR1","unstructured":"Intercept Pharmaceuticals. OCALIVA (obeticholic acid) US Prescribing Information. 2016. http:\/\/www.interconnectsupport.com\/ocaliva_pi.pdf . Accessed 31 May 2016."},{"issue":"3","key":"616_CR2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574\u201382.","journal-title":"Gastroenterology."},{"key":"616_CR3","unstructured":"Dainippon Sumitomo Pharma Co L, Intercept Pharmaceuticals I. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals announce agreement to develop and commercialize obeticholic acid (INT-747) for chronic liver disease [media release]. 30 Mar 2011. http:\/\/www.interceptpharma.com ."},{"key":"616_CR4","unstructured":"Intercept Pharmaceuticals Inc. Intercept Pharmaceuticals submits applications in the U.S. and Europe for marketing approval of obeticholic acid for the treatment of primary biliary cirrhosis [media release]. Jun 29 2015. http:\/\/ir.interceptpharma.com\/releasedetail.cfm?releaseid=919926 ."},{"key":"616_CR5","unstructured":"US Food and Drug Administration. FDA approves Ocaliva for rare, chronic liver disease [media release]. May 31 2016. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm503964.htm ."},{"key":"616_CR6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956\u201365.","journal-title":"Lancet."},{"issue":"17","key":"616_CR7","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569\u201372.","journal-title":"J Med Chem."},{"issue":"Suppl 1","key":"616_CR8","first-page":"605","volume":"42","author":"E Albanis","year":"2005","unstructured":"Albanis E, Alvarez CE, Pruzansky M, et al. INT-747, a novel FXR activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats [abstract no. 1040]. Hepatology. 2005;42(Suppl 1):605\u20136.","journal-title":"Hepatology."},{"issue":"Suppl 2","key":"616_CR9","doi-asserted-by":"crossref","first-page":"S479","DOI":"10.1016\/S0168-8278(15)31536-1","volume":"62","author":"LD Verbeke","year":"2015","unstructured":"Verbeke LD, Mannaerts I, Schierwagen R, et al. Obeticholic acid, an FXR agonist, reduces hepatic fibrosis in a rat model of toxic cirrhosis [abstract no. P0445]. J Hepatol. 2015;62(Suppl 2):S479.","journal-title":"J Hepatol."},{"issue":"Suppl 4","key":"616_CR10","first-page":"347A","volume":"60","author":"F Nevens","year":"2014","unstructured":"Nevens F, Andreone P, Mazzella G, et al. An international phase 3 study of the FXR agonist obeticholic acid in PBC patients: effects on markers of cholestasis associated with clinical outcomes and hepatocellular damage [abstract no. 295]. Hepatology. 2014;60(Suppl 4):347A\u20138A.","journal-title":"Hepatology."},{"issue":"4 Suppl 1","key":"616_CR11","doi-asserted-by":"crossref","first-page":"S1073","DOI":"10.1016\/S0016-5085(16)33622-8","volume":"150","author":"MH Trauner","year":"2016","unstructured":"Trauner MH, Nevens F, Andreone P, et al. Durable response in the markers of cholestasis through 18 months of open-label long term safety extension study of obeticholic acid in primary biliary cirrhosis [abstract no. Sa1579]. Gastroenterology. 2016;150(4 Suppl 1):S1073\u20134.","journal-title":"Gastroenterology"},{"issue":"4","key":"616_CR12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751\u201361.","journal-title":"Gastroenterology."},{"issue":"Suppl 1","key":"616_CR13","first-page":"521A","volume":"62","author":"KV Kowdley","year":"2015","unstructured":"Kowdley KV, Shah H, Mason A, et al. Long-term safety and efficacy of obeticholic acid treatment in primary biliary cirrhosis after more than 4 years of treatment [abstract no. 628]. Hepatology. 2015;62(Suppl 1):521A\u20132A.","journal-title":"Hepatology."},{"issue":"1","key":"616_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/apt.12999","volume":"41","author":"JR Walters","year":"2015","unstructured":"Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015;41(1):54\u201364.","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 2","key":"616_CR15","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(16)00372-X","volume":"64","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Sanyal AJ, MacConell L, et al. Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis [abstract no. THU-488]. J Hepatol. 2016;64(Suppl 2):S294\u20135.","journal-title":"J Hepatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0616-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0616-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0616-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:16:54Z","timestamp":1498328214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0616-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0616-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]}}}